卡瑞利珠单抗+VEGF抑制剂抗血管生成双靶治疗对晚期非小细胞肺癌患者b-FGF、TSGF、VEGF水平的影响  

Effect of Camrelizumab combined with VEGF inhibitor dual-targeting antiangiogenic therapy on basic fibroblast growth factor,tumor specific growth factor,and VEGF levels in advanced non-small cell lung cancer

作　　者：申晓燕 马耀先 李伟 孙桢 方晓瑞 骆许静 SHEN Xiao-yan;MA Yao-xian;LI Wei;SUN Zhen;FANG Xiao-rui;LUO Xu-jing(Department of Oncology,Xuchang Central Hospital,Xuchang 461000,Henan,CHINA)

机构地区：[1]许昌市中心医院肿瘤内科,河南许昌461000

出　　处：《海南医学》2023年第22期3204-3208,共5页Hainan Medical Journal

基　　金：河南省卫生健康委员会项目(编号:LHGJ20210944)。

摘　　要：目的研究卡瑞利珠单抗联合血管内皮生长因子(VEGF)抑制剂进行抗血管生成双靶治疗对晚期非小细胞肺癌(NSCLC)患者碱性成纤维细胞生长因子(b-FGF)、肿瘤特异性生长因子(TSGF)、VEGF水平的影响。方法选取2019年8月至2021年3月许昌市中心医院肿瘤内科收治的63例晚期NSCLC患者为研究对象,按随机数表法分为对照组(n=31)和研究组(n=32)。对照组患者采用常规化疗联合卡瑞利珠单抗治疗,研究组患者在对照组治疗的基础上联合贝伐珠单抗注射液进行抗血管生成双靶治疗,以3周为1个化疗周期,两组根据耐受情况治疗4~6个周期。比较两组患者的疗效,以及治疗前后的血清b-FGF、TSGF、VEGF水平和免疫功能,同时比较两组患者治疗期间的不良反应发生情况。结果研究组患者的治疗总有效率和疾病控制率分别为31.25%、81.25%,明显高于对照组的9.68%、54.84%,差异均有统计学意义(P<0.05);治疗后,两组患者的血清b-FGF、TSGF水平下降,VEGF水平上升,且研究组患者治疗后的血清b-FGF、TSGF、VEGF水平明显低于对照组,差异均有统计学意义(P<0.05);治疗后研究组患者的CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)分别为(67.22±5.07)%、(35.08±4.39)%、1.24±0.19,明显高于对照组的(49.86±6.24)%、(27.60±3.92)%、0.98±0.14,差异均有统计学意义(P<0.05),但两组患者治疗后的CD8^(+)水平比较差异无统计学意义(P>0.05);治疗期间两组患者均未发生Ⅳ级以上不良反应,血液毒性、消化道反应等发生率比较差异均无统计学意义(P>0.05)。结论卡瑞利珠单抗联合VEGF抑制剂行抗血管生成双靶治疗能有效改善晚期NSCLC患者症状,提高疗效,改善免疫功能,且无明显不良反应。Objective To investigate the effect of Camrelizumab+vascular endothelial growth factor(VEGF)inhibitor dual-targeting antiangiogenic therapy on basic fibroblast growth factor(b-FGF),tumor specific growth factor(TSGF),and VEGF levels in patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty-three patients with advanced NSCLC in Department of Oncology,Xuchang Central Hospital from August 2019 to March 2021 were enrolled and randomly assigned into two groups.Control group(n=31)received routine conventional chemotherapy combined with Camrelizumab,and study group(n=32)received Bevacizumab injection dual-targeting antiangiogenic therapy based on the treatment of the control group.Taking 3 weeks of treatment as 1 cycle of chemotherapy,the two groups were treated for 4 to 6 cycles depending on tolerance.Then the clinical efficacy,serum b-FGF,TSGF,and VEGF levels before and after treatment,immune function,and the incidence rate of adverse reactions during treatment were compared between the two groups.Results The response rate and disease control rate were 31.25%and 81.25%in the study group,which were significantly higher than 9.68%and 54.84%in control group(all P<0.05).After treatment,a decrease in serum b-FGF and TSGF levels and an increase in VEGF levels were detected in both groups(P<0.05);levels of b-FGF,TSGF,and VEGF were significantly lower in the study group than in the control group(P<0.05).After treatment,CD3+,CD4+,and CD4+/CD8+values were(67.22±5.07)%,(35.08±4.39)%,and 1.24±0.19 in the study group,which were all significantly higher than(49.86±6.24)%,(27.60±3.92)%,and 0.98±0.14 in the control group(P<0.05),and no statistically significant difference was found in CD8+value between the two groups(P>0.05).No gradeⅣor above adverse reactions occurred in the two groups.The incidence rate of hematotoxicity and gastrointestinal reactions demonstrated no significant difference between the two groups(P>0.05).Conclusion Application of Camrelizumab+VEGF inhibitor dual-targeting antiangiogenic therap

关 键 词：非小细胞肺癌 卡瑞丽珠单抗 血管内皮生长因子抑制剂 抗血管生成双靶治疗 疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤]